EMG
ALDX icon

Ellington Management Group’s Aldeyra Therapeutics ALDX Stock Holding History

Ellington Management Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,800
Closed -$83K – 579
2019
Q2 		$83K Sell
13,800
-1,100
-7% -$8.28K 0.01% 551
2019
Q1 		$135K Buy
+14,900
New +$127K 0.02% 509
2017
Q4 		– Sell
-23,300
Closed -$168K – 576
2017
Q3 		$168K Buy
+23,300
New +$122K 0.03% 552

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Ellington Management Group's ALDX Position: Q3 2019 in Review

Ellington Management Group sold out of Aldeyra Therapeutics (ALDX) in Q3 2019, closing a stake of 13,800 shares — an estimated $83K sold.

Ellington Management Group first reported a position in ALDX in Q3 2017 and held it in 3 quarters. The position peaked at $168K in Q3 2017. 72 funds tracked by Wall St. Rank hold ALDX as of Q3 2019.

  • Ellington Management Group reported no remaining Aldeyra Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Ellington Management Group sold 13,800 Aldeyra Therapeutics shares in Q3 2019, an estimated $83K.
  • Ellington Management Group first reported a position in Aldeyra Therapeutics in Q3 2017 and held it in 3 quarters.
  • Ellington Management Group's Aldeyra Therapeutics position peaked at $168K in Q3 2017.
  • 72 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2019.

Based on Ellington Management Group's 13F filing for Q3 2019, filed 14 Nov 2019.